Ensurge, a cutting-edge medical device manufacturer headquartered in Suzhou, is reportedly in the spotlight for securing a new round of financing that has yielded RMB 100 million. The funding round saw participation from a consortium of investors including TPIC, Legend Capital, and Peakview Capital. The capital raised is earmarked for bolstering the market promotion of Ensurge’s non-host ultrasonic knife and for gearing up the development and manufacturing capabilities of its next-generation energy platform.
Established in 2020, Ensurge earned a significant milestone with the acquisition of a Category III medical device license from China’s National Medical Products Administration (NMPA) in November 2022 for its pioneering split-type ultrasonic knife, which is the first of its kind in the world without a host. This breakthrough product was officially launched in the market during the third quarter of 2023. In just the first half of this year, the product has seen significant adoption, with more than 100 hospitals winning bids for it through centralized procurement, resulting in the product reaching over 200 hospitals.- Flcube.com
